http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103290011-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 2013-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2015-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103290011-B |
| titleOfInvention | The maternal serum relevant to fetal congenital heart disease/blood plasma miRNA mark mir-29c and application thereof |
| abstract | The invention belongs to genetically engineered and reproductive medicine field, disclose the maternal serum relevant to fetal congenital heart disease/blood plasma miRNA mark mir-29c and application thereof.This mark is mi-29c, and fetal congenital heart disease case group and normal healthy controls group differentiation can be opened by this mark well, have good booster action to fetal congenital heart disease early diagnosis. |
| priorityDate | 2013-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 47.